Yourgene® DPYD



DPYD Genotyping

5-fluorouracil (5-FU) is a chemotherapy agent used to treat a range of cancers including colorectal, head and neck, breast, pancreatic and stomach cancer. 5-FU is metabolized by the dihydropyrimidine dehydrogenase enzyme (DPD) which is encoded by the *DPYD* gene.

Several variants within *DPYD* have been described that lead to reduced or abolished DPD activity. Patients with these variants are at an increased risk of severe or fatal 5-FU toxicity. Therefore, implementation of DPD deficiency screening by genotyping will allow a more accurate prediction of toxicity and chemotherapeutic response.

| Allelic Variant | rsID | Nucleotide Change | Protein Change | Allele Function |
|-----------------|------------|-------------------|----------------|-----------------|
| *2A | rs3918290 | c.1905+1G>A | N/A | No Function |
| *13 | rs55886062 | c.1679T>G | p.l560S | No Function |
| N/A | rs67376798 | c.2846A>T | p.D949V | Decreased |
| HapB3 | rs75017182 | c.1129-5923C>G | N/A | Decreased |
| | rs56038477 | c.1236G>A | p.E412E | Decreased |
| | rs56276561 | c.483+18G>A | N/A | Decreased |

Key Benefits

Two tube assay:

- Tube 1 detects mutant sequences for the 6 SNPs in addition to the
- wildtype sequence for the *2A allele to allow determination of zygosity.
- Tube 2 detects the wildtype sequences for the 5 remaining wildtype alleles
- STR Markers are included in each tube to aid sample identification.

6 Clinically Relevant Mutations inline with CPIC Guidelines

Ready to use reagents:

Simply add DNA to the PCR reaction mix.

Rapid Turnaround Time:

- Minimal hands on time 1 day turnaround:
- PCR: ~3 hours.
- Capillary Electrophoresis: ~1 hour.

CE-IVD ensures reliability

Reliable and Accurate Detection

Simple data interpretation:

- Software analysis files for GeneMapper™ and GeneMarker® are provided by Yourgene Health.
- The CPIC guideline provides supplementary information to aid the clinical interpretation of *DPYD* allelic variants, with additional information regarding fluoropyrimidine dose.

Yourgene® DPYD Protocol Overview



1. Reaction Mix Prepare and dispense the *DPYD* reaction mixes into 0.2ml PCR tubes or a 96 well plate.



3. PCR Run thermal cycling program.



5. Analysis
Simple analysis and
interpretation of results
using GeneMapper™ or
GeneMarker® software.




2. DNA Add patient DNA to the dispensed *DPYD* reaction mixes.



4. Capillary Electrophoresis. No post-PCR modifications required. Compatible with ABI 3*** Genetic Analysers.

Example Results



Normal Result

In a normal result, all alleles detected are homozygous wildtype. In this example, the sample is wildtype for all markers detected:

*2A – green WT peak present in the A mix.

*13, c.2846A>T, HapB3 – Green WT peaks present in the B mix

Homozygous Result

In an individual homozygous for a specific mutation, the marker will only display a single mutant peak and no wildtype. In this example, the sample is homozygous mutant for 1679 T>G (blue peak), with the remaining markers showing a homozygous wildtype genotype

Heterozygous Result

If an individual is heterozygous for a marker, two peaks will be detected. In this example, the sample is heterozygous mutant for c.1679 T>G, with the remaining markers showing a homozygous wildtype genotype

Compound Heterozygous Result

If an individual is heterozygous for a marker, two peaks will be detected. In this example, the sample is heterozygous mutant for all haplotype B3 markers (c.1129-5923 C>G, c.1236 G>A, c.483+18 G>A), with the other remaining markers showing a homozygous wildtype genotype

Ordering Information

| Assay | Catalogue Number | Description | Kit Size | | | |
|--|------------------|--|----------|--|--|--|
| Yourgene® DPYD, CE-IVD | ONDYDB1 | DPYD screen testing for *2A, *13, c.2846A>T, HapB3 | 25 Tests | | | |
| Yourgene® DPYD previously known as Elucigene® DPYD | | | | | | |

References

- $\bullet \qquad \textit{DPYD} \ \text{genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis (Henricks et al., 2019)}$
- A cost analysis of upfront DPYD genotype guided dose individualisation in fluoropyrimidine-based anticancer therapy (Henricks et al., 2019)

About

YOURGENE HEALTH

Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling genomic medicine.



For further information Tel: +44 (0) 161 669 8122 Email: info@yourgenehealth.com

yourgenehealth.com

